You are here: Industry Insights > Novartis

News List

Sandoz regulatory submission for proposed biosimilar adalimumab accepted by FDA worldpharmanews
January 17, 2018
Sandos, a global leader in Novartis Pharmaceuticals and Biosimilars, announced today that the U.S. Food and Drug Administration (FDA) has accepted the BLA for Biologics Licenses submitted under section 351 (k)
Novartis' Cosentyx Beats Johnson & Johnson’s Stelara in Head-to-Head Trial biospace
January 17, 2018
Novartis today announced that the results of the CLARITY study demonstrate that Cosentyx® (which provides a clear and nearly dermatological benefit in adults with moderate-to-severe plaque psoriasis at 12 weeks compared to Stelara®
Novartis appoints Elizabeth Barrett as Oncology Head worldpharmanews
January 12, 2018
Novartis today announced that Liz Barrett, the world's president of oncology for Pfizer, Inc., has been named CEO of Novartis Pharmaceuticals and a member of the Novartis Executive Board since February 1, 2018.
Novartis Steals New Oncology Head From Pfizer biospace
January 12, 2018
Novartis has got its new chief of oncology.
GlaxoSmithKline CEO Replaced 50 Top Managers, Lured Execs From Google, Novartis and Teva biospace
January 11, 2018
GlaxoSmithKline Chief Executive Officer Emma Walmsley is not done reshaping her leadership team as she continues to overhaul the company’s pharmaceutical division
Novartis Advances Head-to-Head Superiority Trials of Cosentyx Versus Humira And Proposed Biosimilar biospace
January 10, 2018
Novartis announced today the initiation of SURPASS, a head-to-head clinical trial of Cosentyx® (secukinumab) versus proposed biosimilar adalimumab** in ankylosing spondylitis (AS).
Novartis Announces 2018's Second FDA Breakthrough Tag of the Week biospace
January 05, 2018
A Novartis drug approved as a second-line treatment for a blood disorder snagged the U.S. Food and Drug Administration’s Breakthrough Therapy Designation as a first-line defense.
FDA Hails Novartis' Kisqali a Breakthrough biospace
January 04, 2018
Little more than 10 months after its approval to treat some postmenopausal breast cancer patients, Novartis’ Kisqali (ribociclib) snagged Breakthrough Therapy Designation to treat a new segment of premenopausal breast cancer patients.
New SoCal Biotech Launches With $55.3M Backed by Novartis, Sanofi and 5AM Ventures biospace
January 04, 2018
Expansion Therapeutics officially launched with the close of a $55.3 million Series A financing
Novartis' Tasigna Wins FDA Nod for First and Only CML Therapy biospace
December 28, 2017
Novartis announced today that the US Food and Drug Administration (FDA) approved the inclusion of Treatment-free Remission (TFR) data in the Tasigna® (nilotinib) US product label.

Previous page 1 2 3 4 5 6 7 8 9 10 ... 71 72 Next page